CytomX Therapeutics (CTMX) shares gained more than 1% in Friday afternoon trading after BMO Capital started coverage of the company with an outperform...
CytomX Therapeutics (CTMX) has an average rating of buy and price targets ranging from $6 to $16, according to analysts polled by Capital IQ. (MT Newswires...
CytomX Therapeutics (CTMX) has an average rating of buy and price targets ranging from $6 to $16, according to analysts polled by Capital IQ. (MT Newswires...
CytomX Therapeutics (CTMX) said Thursday it has dosed the first patient in a phase 1 dose-escalation study of CX-904, a drug candidate to fight cancer...
| Address | 151 Oyster Point Boulevard South San Francisco, California 94080-1913 |
| Phone | +1.605.515.3185 |
| Number of Employees | 137 |
| Recent SEC Filing | 06/21/2022 8-K |
| Chairman, President & Chief Executive Officer | Sean A. McCarthy |
| Chief Financial Officer & Senior Vice President | Carlos E. Campoy |
| Senior Vice President & Head-Research | Marcia P. Belvin |
| Chief Medical Officer & Senior Vice President | Alison L. Hannah |
| Price Open | $1.83 |
| Previous Close | $1.83 |
| 52 Week Range | $1.51 - 7.53 |
| Market Capitalization | $120.3 M |
| Shares Outstanding | 65.4 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/04/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.41 |
| Beta vs. S&P 500 | N/A |
| Revenue | $59.5 M |
| Net Profit Margin | -129.97% |
| Return on Equity | -91.89% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
